Fernanda Salazar

Learn More
PURPOSE Survival in patients with advanced non-small-cell lung cancer (NSCLC) who are treated with platinum-based chemotherapy is rather variable. Methylation-dependent transcriptional silencing of 14-3-3sigma, a major G2-M checkpoint control gene, could be a predictor of longer survival. PATIENTS AND METHODS A sensitive methylation-specific polymerase(More)
The potential differential effect of first-line treatment and molecular mechanisms on survival to second-line chemotherapy or EGFR tyrosine kinase inhibitors (TKIs) in non-small-cell lung cancer (NSCLC) has not been fully investigated. In particular, CHFR is frequently methylated in NSCLC and may influence outcome. We analyzed the outcome of second-line(More)
At the time of diagnosis, half of lung cancer patients have advanced incurable disease. Different chemotherapy combinations--with or without targeted therapies--yield similar results in spite of the continuous efforts of clinicians. However, molecular biological studies have already shed a great deal of light on the existence of multiple genetic aberrations(More)
In the single source unsplittable flow problem, commodities must be routed simultaneously from a common source vertex to certain destination vertices in a given digraph. The demand of each commodity must be routed along a single path. In a groundbreaking paper Dinitz, Garg, and Goemans [4] prove that any given (splittable) flow satisfying certain demands(More)
In spite of the dismal outcome of glioblastoma multiforme (GBM), we are in a position to provide a ray of hope to patients and families. Methylation of MGMT in tumor occurs in approximately a third of patients and predicts meaningful response and survival to adjuvant radiotherapy plus temozolomide. Limited access to tumor tissue in some patients could be(More)
7056 Background: CHFR (checkpoint with forkhead-associated and ring finger) regulates a prophase delay in cells exposed to agents that disrupt microtubules. Epigenetic inactivation of CHFR is a frequent event in human tumors, leading to impaired checkpoint function and enhanced sensitivity to docetaxel. We hypothesized that serum DNA methylation of CHFR(More)
e21025 Background: Genetic diversity in lung cancer according to histological subtype has not been fully explored. BRCA1 and RAP80 influence response to chemotherapy. Musashi 2 activates HES-1 in the Notch pathway, and HES-1 can abrogate CYLD. A20, AEG-1, EZH2 and TRAF6 are also involved in NFkB activation. We have examined mRNA expression of BRCA1, RAP80(More)
7590 Background: Progression-free survival (PFS) in EGFR-mutant NSCLC p treated with erlotinib is unpredictable at the individual level. The initial presence of double mutations (EGFR L858R or del 19 plus T790M) is associated with shorter PFS. We hypothesized that the site of mets and/or prior chemotherapy could also influence outcome in these p with double(More)
7586 Background: Little is known about the potential effect of genetic alterations in the NFkB and Notch pathways on NSCLC p. Musashi 2 activates HES-1 in the Notch pathway, and HES-1 can abrogate CYLD. A20, AEG-1, EZH2 and TRAF6 are also involved in NFkB activation. BRCA1 and RAP80 are modulators of cisplatin-based chemotherapy. Mutations in NFKBIA and(More)
  • 1